Dataset from LUX-Breast 2; An Open Label, Phase II Trial of Afatinib (BIBW 2992) in Patients With Metastatic HER2-overexpressing Breast Cancer Failing HER2-targeted Treatment in the Neoadjuvant and/or Adjuvant Treatment Setting

The general aim of this study is to investigate the efficacy and safety of afatinib (BIBW
2992) alone and in combination with weekly paclitaxel or weekly vinorelbine (in patients who
progress on afatinib monotherapy within this trial) as treatment in patients with
HER2-overexpressing, metastatic breast cancer, who failed HER2-targeted treatment in the
neoadjuvant or adjuvant setting